Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALI) saw a significant decrease in short interest in January. As of January 15th, there was short interest totalling 66,300 shares, a decrease of 96.4% from the December 31st total of 1,840,000 shares. Based on an average trading volume of 1,270,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 2.4% of the company’s shares are short sold.

Institutional Investors Weigh In On Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. JPMorgan Chase & Co. bought a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned about 0.54% of Palisade Bio at the end of the most recent quarter. Hedge funds and other institutional investors own 11.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on PALI shares. Brookline Capital Management started coverage on shares of Palisade Bio in a research note on Wednesday, November 20th. They issued a “buy” rating and a $38.00 price target for the company. Maxim Group decreased their price objective on Palisade Bio from $22.50 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Palisade Bio Price Performance

Shares of PALI opened at $1.43 on Thursday. The business’s 50 day moving average price is $1.86 and its 200-day moving average price is $2.93. Palisade Bio has a 52 week low of $1.33 and a 52 week high of $11.75.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter, topping analysts’ consensus estimates of ($3.35) by $1.03. On average, analysts forecast that Palisade Bio will post -12.43 EPS for the current year.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.